Research: Single-Tablet HIV Therapy

Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial – The Lancet HIV (free)

Commentaries: Towards a universal second-line fixed-dose combination ART – The Lancet HIV (free) AND Single-Tablet ART: New Hope in HIV Therapy? All-in-one fixed dose combo proves safe, effective in EMERALD trial – MedPage Today (free registration required) AND EMERALD Trial: Week 48 Results Demonstrate Efficacy in Single-Tablet HIV Therapy – Infectious Diseases Advisor (free)

Study Presented at #IDWeek2017